Released Nov 3, 2015, after the close
10-Q filed Nov 3, 2015, 34 days after period end · 0001104659-15-075283
Q3 2015 · 10-Q
Revenue$1.03M$1.03M no prior Q3 2014 on file+211.9% vs Q2 2015
Net Income-$6.89M-$6.89M N/M vs Q3 2014N/M vs Q2 2015
EPS Diluted-$0.24-$0.24 N/M vs Q3 2014N/M vs Q2 2015
Operating Income-$6,328,000N/M
Operating Cash Flowderived-$7,131,000N/M
Free Cash Flowderived-$7,786,000N/M
Margins · derived
Operating margin-616.8%
Net margin-671.2%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2015 | Q3 2014 | Q3 2013 | Q3 2012 |
|---|---|---|---|---|
| Revenue | $1.03M | — | $209.00K | $528.00K |
| Net Income | -$6.89M | -$6.60M | -$6.07M | -$4.11M |
| EPS Diluted | -$0.24 | -$0.32 | -$4.81 | -$3.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR